Literature DB >> 7477012

The frequency of the mitochondrial aldehyde dehydrogenase I2 (atypical) allele in Caucasian, Oriental and African black populations determined by the restriction profile of PCR-amplified DNA.

F Dandré1, A Cassaigne, A Iron.   

Abstract

The aldehyde dehydrogenase I (ALDH I) gene codes for a mitochondrial enzyme which plays a major role in hepatic alcohol detoxication. It has been related to alcohol flushing in Orientals bearing the atypical ALDH I2 gene. The variant protein results from a lysine for glutamate substitution at position 487 (G-->A change in exon 12). A procedure for ALDH I2 detection consisting in a differentiation between the 'atypical' allele and the 'wild' allele has been improved through PCR and subsequent MboII digestion. Blood samples collected on anticoagulant or directly absorbed on blotting paper were used for DNA amplification in the presence of two specific oligonucleotidic primers, each one able to incorporate a restriction site in the amplimer. After MboII digestion, PCR products were separated by polyacrylamide gel electrophoresis and then visualized with ethidium bromide. This technique permits a rapid and non-radioactive detection of atypical ALDH I2 on a PCR product without the use of allele specific oligonucleotides. It was applied to the study of ALDH I2 allele frequency in random population samples of three ethnic groups: Caucasians, Orientals and African blacks.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7477012     DOI: 10.1006/mcpr.1995.0030

Source DB:  PubMed          Journal:  Mol Cell Probes        ISSN: 0890-8508            Impact factor:   2.365


  8 in total

1.  Interaction between the functional polymorphisms of the alcohol-metabolism genes in protection against alcoholism.

Authors:  C C Chen; R B Lu; Y C Chen; M F Wang; Y C Chang; T K Li; S J Yin
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

2.  Asian flushing presents opportunities for disease prevention.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2016-11       Impact factor: 4.599

Review 3.  Targeting aldehyde dehydrogenase 2: new therapeutic opportunities.

Authors:  Che-Hong Chen; Julio Cesar Batista Ferreira; Eric R Gross; Daria Mochly-Rosen
Journal:  Physiol Rev       Date:  2014-01       Impact factor: 37.312

4.  Interaction of DRD2TaqI, COMT, and ALDH2 genes associated with bipolar II disorder comorbid with anxiety disorders in Han Chinese in Taiwan.

Authors:  Ming-Chuan Hu; Sheng-Yu Lee; Tzu-Yun Wang; Yun-Hsuan Chang; Shiou-Lan Chen; Shih-Heng Chen; Chun-Hsien Chu; Chen-Lin Wang; I Hui Lee; Po See Chen; Yen Kuang Yang; Ru-Band Lu
Journal:  Metab Brain Dis       Date:  2014-11-29       Impact factor: 3.584

5.  Allelic variation at alcohol metabolism genes ( ADH1B, ADH1C, ALDH2) and alcohol dependence in an American Indian population.

Authors:  Connie J Mulligan; Robert W Robin; Michael V Osier; Nyamkhishig Sambuughin; Lev G Goldfarb; Rick A Kittles; Diane Hesselbrock; David Goldman; Jeffrey C Long
Journal:  Hum Genet       Date:  2003-07-12       Impact factor: 4.132

Review 6.  Can gene therapy be used to prevent cancer? Gene therapy for aldehyde dehydrogenase 2 deficiency.

Authors:  Rachel A Montel; Carlos Munoz-Zuluaga; Katie M Stiles; Ronald G Crystal
Journal:  Cancer Gene Ther       Date:  2021-11-19       Impact factor: 5.854

7.  The aldehyde dehydrogenase 2 polymorphisms on neuropsychological performance in bipolar II disorder with or without comorbid anxiety disorder.

Authors:  Ru-Band Lu; Yun-Hsuan Chang; Tzu-Yun Wang; Sheng-Yu Lee; Po See Chen; Yen Kuang Yang
Journal:  PLoS One       Date:  2018-02-09       Impact factor: 3.240

8.  ALDH2 Gene: Its Effects on the Neuropsychological Functions in Patients with Opioid Use Disorder Undergoing Methadone Maintenance Treatment.

Authors:  Po-Wei Lee; Tzu-Yun Wang; Yun-Hsuan Chang; Sheng-Yu Lee; Shiou-Lan Chen; Ze-Cheng Wang; Po See Chen; Chun-Hsien Chu; San-Yuan Huang; Nian-Sheng Tzeng; I Hui Lee; Kao Chin Chen; Yen Kuang Yang; Jau-Shyong Hong; Ru-Band Lu
Journal:  Clin Psychopharmacol Neurosci       Date:  2020-02-29       Impact factor: 2.582

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.